Physical Activity and the Course of COVID-19

January 6, 2023 updated by: Edyta Sutkowska, Wroclaw Medical University

The Level of Usual Physical Activity and Its Impact on the Course of COVID-19 in Hospitalized Patients.

Being active has a beneficial effect on human immunology. Patients hospitalized for COVID-19 (coronavirus disease 2019) will be surveyed for their prior physical activity. In order to show the relationship between the level of usual physical activity and the course of the disease, the following variables will be monitored to express the disease severity: death or transfer to ICU (intensive care unit), or recovery, also the length of hospitalization will be analyzed as a secondary outcome. Depending on the availability of data, the following will also be analyzed: complications other than respiratory failure, C-reactive protein (CRP) and procalcitonin (PCT) levels on admission, and other laboratory parameters, need for oxygen therapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The aim of the study is to assess the relationship between the level of physical activity before falling ill with COVID-19 (coronavirus disease 2019) and the severity of the disease. The course of the disease is often surprising and independent of factors that have been selected as poor prognostic factors ( e.g. diabetes, obesity), therefore it is advisable to look for a relationship for those variables that have not yet been analyzed.

Methodology:

To show if the usual physical activity impacts the course of COVID-19 the relationship between the results from the modified, short form of IPAQ (International Physical Activity Questionnaire) and the disease termination (death or transfer to intensive care unit or recovery) as well as the hospitalization length will be analyzed. The modification of the questionnaire is necessary due to the specific course of COVID-19, thus the patients will be asked about the "usual" physical activity before the disease (not about the last 7 days).

After written consent patients (age >= 18) from the temporal hospital, dedicated to COVID-19, will be surveyed with IPAQ. If the patient's condition is too poor, the patient will be able to: provide answers on a different day up to 7 days from discharge from the hospital, or indicate a relative who can answer for him/her. The basic laboratory parameters e.g.: morphology, C-reactive protein, procalcitonin, kidney and liver function, D-dimer, gasometry, and X-rays picture of the lungs will be collected from the patient's medical record if available. Also, information about the type and duration of the used ventilation will be collected if available.

Study Type

Observational

Enrollment (Actual)

140

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Poland
    • Lower Silesia
      • Wroclaw, Lower Silesia, Poland
        • Wroclaw Medical University
    • Upper Silesia
      • Bytom, Upper Silesia, Poland
        • Medical University of Silesia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized due to COVID-19 (confirmed COVID-19 infection by PCR method or equivalent diagnostic technique) at the COVID-19 treatment unit

Description

Inclusion Criteria:

  • age >=18
  • confirmed COVID-19 ( coronavirus disease 2019) infection
  • hospitalization in the COVID-19 treatment unit

Exclusion Criteria:

  • pregnancy;
  • inability to complete the questionnaire during hospitalization or up to a week after discharge;
  • history of a significant cardiovascular event in the last 6 months (acute coronary syndrome, stroke, amputation, revascularization of peripheral vessels, pulmonary or peripheral embolism of any etiology) if the patient did not complete the rehabilitation process;
  • symptomatic chronic respiratory disease not responding to therapy before hospitalization for COVID-19 (or no therapy);
  • any dyspnea at rest in the last month before COVID-19;
  • injury to the locomotor system in the last month before contracting COVID-19;
  • hospitalization in the last month before contracting COVID-19.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
COVID-19
Adults aged 18 at the least of any sex and race hospitalized for SARS-CoV-2 infection
Other: completing surveys
The level of "usual" physical activity before the disease ( COVID-19- coronavirus disease 2019) will be analysed based on the IPAQ ( International Physical Activity Questionnaire) results.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
death
Time Frame: From the date of admission to hospital until the date of death; assessed up to 5 months
death due to COVID-19 ( coronavirus disease 2019) complication of the disease
From the date of admission to hospital until the date of death; assessed up to 5 months
recovery
Time Frame: From the date of admission to hospital until the date of a dismission from the hospital; assessed up to 5 months
patient discharged home from hospital
From the date of admission to hospital until the date of a dismission from the hospital; assessed up to 5 months
transfer to intensive care unit (ICU)
Time Frame: From the date of admission to hospital until the date of transfer to ICU; assessed up to 5 months
patient moved to intensive care unit
From the date of admission to hospital until the date of transfer to ICU; assessed up to 5 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
hospitalization length
Time Frame: From the date of admission to hospital until the date of death, transfer to ICU or discharge home;assessed up to 5 months
days spent in hospital before: death, transfer to ICU or recovery
From the date of admission to hospital until the date of death, transfer to ICU or discharge home;assessed up to 5 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Wroclaw Medical University

Collaborators

Medical University of Silesia

Investigators

  • Study Chair: Edyta Sutkowska, PhD, Wroclaw Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 3, 2022

Primary Completion (Actual)

March 31, 2022

Study Completion (Actual)

September 30, 2022

Study Registration Dates

First Submitted

January 14, 2022

First Submitted That Met QC Criteria

January 19, 2022

First Posted (Actual)

January 21, 2022

Study Record Updates

Last Update Posted (Estimate)

January 9, 2023

Last Update Submitted That Met QC Criteria

January 6, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1081/2021

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

All IPD that underlie results in a publication: results of IPAQ, data about the primary and secondary outcomes, laboratory tests, also statistical analysis will be available at the link connected with URN: urn:umed-wroc-prod:UMW9cf7247169fc4d2b8dad0921ad2207fb after publishing; other supporting documents will be available as supplementary materials accompanying the article after publishing

IPD Sharing Time Frame

  1. after publication with no time limit for IPD
  2. supplementary materials - depends on the publisher

IPD Sharing Access Criteria

  1. under processing of determined- for IPD
  2. according to the publisher law- for the supplementary materials

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)
  • Informed Consent Form (ICF)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on completing surveys

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe